Neurona Therapeutics

Dr. Jonathon Parker, MD, PhD, Epilepsy and Functional Neurosurgeon at the Mayo Clinic Arizona, and a principal investigator evaluating Neurona’s lead cell therapy candidate, NRTX-1001, in ongoing clinical trials for drug-resistant epilepsy, recently sat down with NeurologyLive to discuss the thought process and promise behind cell therapy approaches in epilepsy. The full interview and article can be found here: https://lnkd.in/eA2kCg-H

Neurona Therapeutics is thrilled to announce plans to initiate the Phase 3 EPIC clinical trial for its lead product candidate, NRTX-1001. The advancement of NRTX-1001 into the Phase 3 EPIC trial follows productive discussions with the U.S. Food and Drug Administration under an RMAT designation granted in June 2024. Read all about it here: https://lnkd.in/gEYWP-H7

On International Epilepsy Day, Neurona Therapeutics stands with the epilepsy community to advocate for more research, greater awareness, and better treatment options for those affected by this condition. One-third of people with epilepsy continue to live with uncontrolled seizures because current treatments aren’t effective for them. At Neurona, we’re committed to developing innovative therapies that could provide life-changing relief for such individuals. For 2024’s Epilepsy Awareness Month, we wore purple to raise awareness and support for those impacted by epilepsy, and we're proud to continue our mission every day. #EpilepsyDay #Epilepsy #Neurona #RegenerativeMedicine

We’re excited to be part of the 24th Precision Medicine World Conference, the premier forum for leaders shaping the future of healthcare! Co-hosted by Stanford and UCSF, this year’s conference will take place from February 5-7, 2025, at the Santa Clara Convention Center. Marina Bershteyn, PhD, Director of Discovery Research, will present an update on our significant progress in developing interneuron cell therapy for drug-resistant epilepsy during Showcase Track S1 on emerging therapeutics. Her session is scheduled for February 7th, from 2:15 PM – 2:30 PM. With over 400 speakers, 12 tracks, and honorees like Nobel Laureates Carolyn Bertozzi, Drew Weissman, and Carol Greider, as well as leaders like NVIDIA’s CEO Jensen Huang and FDA Commissioner Rob Califf, this is a fantastic opportunity to share breakthroughs and build collaborations that will shape the future of precision medicine. Learn more: https://lnkd.in/dk2yvMDy #PMWC25 #Neurona #Epilepsy #RegenerativeMedicine PMWC - Precision Medicine World Conference Tal Behar

This week, we gathered to celebrate the Lunar New Year and honor the traditions behind this global holiday. It was a meaningful event filled with delicious Chinese food and an insightful presentation by Eric Steven Sevilla, who shared the history and significance of Lunar New Year and how it is celebrated across different cultures. As we welcome the Year of the Snake, we reflect on values of renewal, growth, and creativity. Chúc M?ng N?m M?i (Vietnamese), Kung Hei Fat Choi (Cantonese), and Xīnnián Kuàilè (Mandarin) — greetings of luck and new beginnings. Events like this serve as reminders of the diversity that makes Neurona a special place to work and thrive together. #LunarNewYear #Neurona #RegenerativeMedicine

Today we honor the memory of Dr. Martin Luther King Jr. His life and legacy continue to inspire us in working toward the greater good. A hero for his tireless work for civil rights for the African American community, Dr. King’s influence speaks to equality across lines that too easily divide us. Long live his message of justice, compassion, and human dignity.

We are proud to announce that Catherine Priest, PhD, Chief Development Officer, will be a panelist at the upcoming ISSCR Nucleus Forum this Sunday, January 12th at 8:30 am. The panel will tackle critical topics in the development and commercialization of cell and gene therapies, offering insights into navigating the complexities of translating research breakthroughs into impactful patient treatments. Dr. Priest’s extensive experience in developing cellular therapeutics will provide a valuable perspective to this important discussion. Learn More: https://lnkd.in/g6tdBUbK #Neurona #Epilepsy #RegenerativeMedicine?

Great to be mentioned (and quoted) in Nature's feature: "Stem cells head to the clinic: treatments for cancer, diabetes and Parkinson’s disease could soon be here". You can read the full article at the following link: https://lnkd.in/g-kJBgJx

We're delighted to be included in MIT Technology Review's "10 Breakthrough Technologies for 2025". Follow the link here to read more: https://lnkd.in/gciu3uwf

We’re thrilled to announce our team’s newest preprint publication titled “Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity followed by gradual electrochemical maturation” on bioRxiv. This work, led by Neurona Therapeutics' Marina Bershteyn, PhD, Hongjun(Robin) Zhou, PhD, and Lucho Fuentealba, PhD, sheds light on the development, fate, and function of NRTX-1001 MGE pallial-type GABAergic interneurons derived from human pluripotent stem cells. Pallial or cortical interneuron loss of function leads to epilepsy and contributes to other neurological disorders. Restoration of cortical interneurons, using a novel regenerative cell therapy approach, such as NRTX-1001, represents a promising therapeutic strategy and has yielded an encouraging preliminary safety and efficacy signal in an ongoing multicenter, open-label Phase 1/2 clinical trial in drug-resistant mesial temporal lobe epilepsy. A big thank you to all the authors of this preprint, Chun Chen and Jorge Palop at the Gladstone Institute, and the incredible team at Neurona Therapeutics for their hard work and dedication in making a significant advance in our understanding of human interneuron development and regeneration. We’re excited for what’s to come as we continue to advance our cell therapy programs! Read the full paper here: https://lnkd.in/gARcMHP6 #Neurona #Epilepsy #RegenerativeMedicine